Pancreatic Cancer Research

Clinical trialPhase 3Withdrawn

An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

An Open-Label Extension Study to Evaluate the Safety and Efficacy of Oral Methylnaltrexone Bromide Tablets in Subjects With Advanced Pancreatic Cancer

Outcome
Stopped earlyDue to pandemic challenges and consideration of a different study design in the future. (Other)
Phase
Phase 3
Status
Withdrawn
Study type
Interventional
Planned start
3 February 2020
Planned end
3 February 2024
Enrollment
0 participants
Sites
0
Primary outcomes
Overall Survival
Sponsor type
Industry
Results posted
No
Last update
7 May 2021

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This open-label extension study will evaluate the long-term safety and efficacy of oral MNTX in participants with advanced pancreatic cancer (adenocarcinoma) who were previously enrolled in Study SAL-REL-2042 (NCT04083651).